Victor M Karpyak
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Victor M Karpyak as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:08 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT03818191 · Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment OutcomeMayo Clinic · completed · Alcohol Use Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Genomics of Alcohol Withdrawal and Treatment Response to BenzodiazepinesR01AA030273 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2023 to 2026 · $375,271 awarded in 2026Same name and institution; not confirmed by an ID
- Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo ClinicU01AA026974 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2024 to 2026 · $355,080 awarded in 2026Same name and institution; not confirmed by an ID
- Neurosteroids and Alcohol Use DisorderR01AA031965 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2025 to 2026 · $700,490 awarded in 2026Same name and institution; not confirmed by an ID
- Pharmacogenomics of Acamprosate Treatment Outcome (Supplement)U01AA027487 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2018 to 2023 · $155,616 awarded in 2023Grant number is on one of their registry trials
- IMPACT OF SEX-RELATED HORMONE LEVELS AND GENETIC VARIATION ON ALCOHOL USE DISORDERS AND RELATED PHENOTYPES IN MALES AND FEMALESR21AA026875 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2019 to 2020 · $228,563 awarded in 2020Same name and institution; not confirmed by an ID
- Pharmacogenomics of Treatment Outcomes in Alcohol Use DisordersR21AA025214 · NIAAA · MAYO CLINIC ROCHESTER · fiscal years 2016 to 2017 · $149,063 awarded in 2017Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alcohol Use Disorder: Acamprosate Pharmacometabolomics-informed PharmacogenomicsR01AA027486 · NIAAA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho, Richard M. Weinshilboum · fiscal years 2018 to 2026Named on NCT03818191
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:08 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.J Clin Psychopharmacol · 201441 citationsRCR 1.5
- Changes in heart rate variability in response to treatment with electroconvulsive therapy.J ECT · 200421 citationsRCR 0.8
- 6 citationsRCR 0.2